Abstract 2047P
Background
Despite significant advances in prevention and treatment, febrile neutropenia (FN) remains a common and serious complication of chemotherapy. Leverages data related to G-CSF use are missing. This study aims to (1) describe the practices of G-CSF treatment implementation; (2) identify and measure the decision criteria related to their implementation in patients with breast (BC), lung (LC), or gastrointestinal cancers (GIC), in ambulatory settings, beyond the usual recommendations.
Methods
This non-interventional, cross-sectional, multicenter study required clinical cases presented using conversational interfaces (chatbot), simulating a conversation with one or several virtual interlocutors by voice or text exchange.
Results
The questionnaire was completed by 102 physicians. Most practitioners (84.5%) reported prescribing G-CSF, regardless of tumor type (Table). G-CSF was prescribed more frequently for adjuvant/neoadjuvant therapy than for metastatic cases. Leading factors motivating the prescription were chemotherapy regimen, comorbidities, and age (in 56.7% of cases). Access to care was cited as a reason to prescribe G-CSF.
Table: 2047P
Levels and reasons of G-CSF prescription in all 3 cancer types
Breast cancer | Lung cancer | Gastro Intestinal cancer | Total | ||
Implementation of a G-CSF treatment N (%) | N | 77 | 57 | 60 | 194 |
Yes | 68 (88.3%) | 42 (73.7%) | 54 (90.0%) | 164 (84.5%) | |
Not | 9 (11.7%) | 15 (26.3%) | 6 (10.0%) | 30 (15.5%) | |
What should be considered before prescribing a G-CSF for this patient? N (%) | N | 68 | 42 | 54 | 164 |
Chemotherapy Protocol | 23 (33.8%) | 9 (21.4%) | 7 (13.0%) | 39 (23.8%) | |
Chemotherapy Protocol + comorbidities | 12 (17.6%) | 2 (4.8%) | 8 (14.8%) | 22 (13.4%) | |
Chemotherapy Protocol + Age | 2 (2.9%) | 6 (14.3%) | 2 (3.7%) | 10 (6.1%) | |
Chemotherapy Protocol + comorbidities + age | 31 (45.6%) | 25 (59.5%) | 37 (68.5%) | 93 (56.7%) |
Conclusions
Our findings suggest that ESMO recommendations are broadly followed. In most cases, G-CSF is prescribed in early stages and in curative intent. Despite a large use of G-CSF, education about febrile neutropenia and risk factors should be disseminated to a wide audience.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Viatris.
Funding
Viatris.
Disclosure
F. Scotté: Financial Interests, Personal, Speaker, Consultant, Advisor: Leo Pharma, Pierre Fabre Oncology, MSD, Amgen, Helsinn, BMS, Pfizer, Thermo Fisher, Alliance Healthcare, Biogaran, Sandoz, Sanofi, Pharmanovia, Viatris.
Resources from the same session
2056P - Hospitalization, reconsultations and mortality in the field of oncological emergencies: Who is at higher risk?
Presenter: Eugenia María Martínez Madrid
Session: Poster session 06
2057P - Prevalence of frailty in long-term prostate cancer survivors after radical prostatectomy and its association with quality of life and emotional health
Presenter: Valentin Meissner
Session: Poster session 06
2058P - Reducing waste to improve sustainability and affordability of cancer treatment: Redispensing unused oral anticancer drugs
Presenter: Lisa-Marie Smale
Session: Poster session 06
2059P - The impact of a dental oncology clinic for patients (pts) prescribed bone-modifying agents (BMA) in a cancer centre
Presenter: Harriet Byrne
Session: Poster session 06
2060P - Prevalence and predictor of poor mental adjustment to cancer before lung cancer surgery
Presenter: Junhee Park
Session: Poster session 06
2061P - Network analysis of comprehensive concerns in patients with cancer: Differences between the sexes
Presenter: Kazumasa Yamamoto
Session: Poster session 06
2062P - The psychological distress (PsyD) evaluation in pancreatic cancer (PC) patients (pts): A mono-institutional analysis
Presenter: Maria Bensi
Session: Poster session 06
2063P - Lifestyle changes as cancer treatment: It is time to get specific with our patients
Presenter: Ana Isabel Martin Quesada
Session: Poster session 06
2064P - Hospitalisation of patients with cancer: Identifying points for improvement in patient care in a university hospital in Spain
Presenter: Silvia Roa
Session: Poster session 06
2065P - Communication on the first medical oncology appointment: What do cancer patients want?
Presenter: Rodrigo Vicente
Session: Poster session 06